Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection

The Lancet

Volumn 343, Issue 8902, 1994, Pages 871-881

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AIDS RELATED COMPLEX; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRELAND; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; UNITED KINGDOM;

EID: 0028344275     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(94)90006-X     Document Type: Article

References (28)

1. The efficacy of azidothymidine (AZT) in the treatment of participants with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial
2. Zidovudine in asymptomatic human immunodeficiency virus infection
3. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection
4. Preliminary analysis of the Concorde trial
5. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection
6. Consistency of routine measurements of CD4+, CD8+ peripheral blood lymphocytes
7. The effects of indomethacin and naproxen on zidovudine pharmacokinetics
8. Simultaneous quantification of zidovudine and its metabolites in serum and urine by high-performance liquid chromatography using a column-switching technique
9. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome
10. Design and analysis of randomized clinical trials requiring prolonged observation of each participant, I: introduction and design
11. Design and analysis of randomised clinical trials requiring prolonged observation of each participant, II: analysis and examples
12. Regression models and life tables
13. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus
14. CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine
15. Surrogate endpoints in clinical trials
16. Seropositivity for HIV and development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort
17. CD4 + lymphocyte response to zidovudine as a predictor of AIDS-free time and survival time
18. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection
19. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter
20. Placebo-controlled trial to evaluate zidovudine in treatment of human immunodeficiency virus infection in asymptomatic participants with hemophilia
21. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomised, double-blind placebo-controlled study
22. Randomised double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1
23. Zidovudine now or later?
24. Antiretroviral therapy for adult HIV-infected patients: recommendations from a state-of-the-art conference
25. AIDS prevention trial seeks answers: ComPACT-1
26. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus